Horndalsveen H, Haakensen VD, Madebo T, Grønberg BH, Halvorsen TO, Bjaanæs MM, Danielsen BK, Børve M, Kokkvoll S, Dalen Boda TS, Öjlert ÅK, Helland Å (2026)
ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab
J Thorac Oncol, 103992 (in press)
DOI 10.1016/j.jtho.2026.103992, PubMed 42336205

Thunold S, Hernes E, Gyland Mikalsen LT, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Helland Å, Malinen E, Haakensen VD (2026)
Dual-time-point [¹⁸F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy
EJNMMI Res (in press)
DOI 10.1186/s13550-026-01469-x, PubMed 42322509

Lombardi P, Ramon-Gil E, Raja RQ, Brunetti L, Manfredi GF, Zhou Z, Merces G, Cappuyns S, Fulgenzi CAM, D'Alessio A, Torkpour A, Celsa C, Stefanini B, Yang H, Crowley F, Marron TU, Saeed A, Pinter M, Scheiner B, Huang YH, Lee PC, Nishida N, Po-Ting Lin R, Dalbeni A, Vivaldi C et al. (2026)
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma
J Hepatol (in press)
DOI 10.1016/j.jhep.2026.05.018, PubMed 42297215